Results 171 to 180 of about 106,373 (291)

Ablative radiotherapy in castration‐resistant prostate cancer

open access: yesBJU International, Volume 138, Issue 4, Page 659-665, October 2026.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher   +9 more
wiley   +1 more source

Migration status and urologic health inequities: a scoping review. [PDF]

open access: yesCurr Opin Urol
Goodarzi K   +4 more
europepmc   +1 more source

Function drives 1‐year decision regret in radical prostatectomy: a multicentre prospective study

open access: yesBJU International, Volume 138, Issue 4, Page 694-704, October 2026.
Objectives To identify contemporary drivers of postoperative decision regret 1 year after radical prostatectomy (RP). Patients and Methods In this prospective, multicentre study, patients undergoing robot‐assisted RP (RARP) or retropubic open RP (ORP) for localised prostate cancer at seven centres in Germany and Austria (2022–2024) completed ...
Christopher Hirtsiefer   +14 more
wiley   +1 more source

Robot-assisted urologic surgery after kidney transplantation: indications, graft-protection strategies, and outcomes-a scoping review. [PDF]

open access: yesJ Robot Surg
Drobot RB   +9 more
europepmc   +1 more source

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

open access: yesBJU International, Volume 138, Issue 4, Page 607-619, October 2026.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan   +13 more
wiley   +1 more source

Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1‐LaserComplete study)

open access: yesBJU International, Volume 138, Issue 4, Page 705-713, October 2026.
Objectives To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive ...
Martin J. Connor   +20 more
wiley   +1 more source

Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice

open access: yesBJU International, Volume 138, Issue 4, Page 558-564, October 2026.
Objectives To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle‐invasive bladder cancer (MIBC), and to determine whether trial‐derived evidence can inform response evaluation in contemporary practice. Subjects/Patients and Methods We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for ...
Roberto Contieri   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy